stoxline Quote Chart Rank Option Currency Glossary
  
Alterity Therapeutics Limited (ATHE)
2.02  0.21 (11.6%)    03-27 16:00
Open: 1.77
High: 2.02
Volume: 101,620
  
Pre. Close: 1.81
Low: 1.77
Market Cap: 15(M)
Technical analysis
2024-03-27 4:51:21 PM
Short term     
Mid term     
Targets 6-month :  2.38 1-year :  2.78
Resists First :  2.03 Second :  2.38
Pivot price 1.76
Supports First :  1.73 Second :  1.54
MAs MA(5) :  1.81 MA(20) :  1.76
MA(100) :  2.14 MA(250) :  2.5
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  63.9 D(3) :  48.4
RSI RSI(14): 60
52-week High :  5.4 Low :  1.54
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ATHE ] has closed It is unclear right now based on current values. 59.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.02 - 2.03 2.03 - 2.04
Low: 1.75 - 1.76 1.76 - 1.77
Close: 2 - 2.02 2.02 - 2.03
Company Description

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Headline News

Tue, 26 Mar 2024
Alterity Therapeutics receives A$3.9M research & development tax incentive refund - Seeking Alpha

Fri, 23 Feb 2024
Alterity stock drops on capital raise (NASDAQ:ATHE) - Seeking Alpha

Tue, 06 Feb 2024
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After ... - Barron's

Tue, 05 Dec 2023
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data - Yahoo Finance

Mon, 04 Dec 2023
Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Markets Insider

Mon, 04 Dec 2023
Why Is Neurodegenerative Disease-Focused Alterity Therapeutics (ATHE) Stock Trading Over 200% Higher Toda - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 9 (M)
Shares Float 2,540 (M)
Held by Insiders 0 (%)
Held by Institutions 1 (%)
Shares Short 38 (K)
Shares Short P.Month 30 (K)
Stock Financials
EPS -1.64
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -348.4 %
Return on Assets (ttm) -29 %
Return on Equity (ttm) -53.8 %
Qtrly Rev. Growth -20.3 %
Gross Profit (p.s.) 0
Sales Per Share 0.39
EBITDA (p.s.) -1.47
Qtrly Earnings Growth 0 %
Operating Cash Flow -15 (M)
Levered Free Cash Flow -10 (M)
Stock Valuations
PE Ratio -1.24
PEG Ratio 0
Price to Book value 202
Price to Sales 5.14
Price to Cash Flow -1.21
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android